A Study to Evaluate the Combination of Pegylated Interferon Alfa Plus Valopicitabine in Patients With Hepatitis C
Completed
Merck Sharp & Dohme Corp.
Phase 2
This Phase II study is being conducted in treatment-naive patients (no previous antiviral
therapy for Hepatitis C infection) with genotype-1 chronic hepatitis C to evaluate the safety
and effectiveness of valopicitabine alone and together with Pegylated Interferon (a drug
approved by the Food and Drug Administration for the treatment of Hepatitis C infection).
Valopicitabine When Administered Alone and in Combination With Interferon to Treatment-Naive Patients With Hepatitis C
Completed
Merck Sharp & Dohme Corp.
Phase 1/Phase 2
This study is being conducted in treatment-naive patients (no previous hepatitis C treatment)
to evaluate the safety of valopicitabine (NM283) alone and together with pegylated
interferon, a drug approved by the Food and Drug Administration for the treatment of
hepatitis C infection. This study is also evaluating the ability of valopicitabine to
decrease the amount of hepatitis C virus in the body. The results for patients taking
valopicitabine alone will be compared with the results for patients taking valopicitabine
together with pegylated interferon.
Valopicitabine Alone and Together With Pegylated Interferon in Patients With Chronic Hepatitis C Who Have Failed to Respond to Standard Therapy
Completed
Merck Sharp & Dohme Corp.
Phase 2
This study is being conducted to compare the safety, effectiveness and tolerance of
valopicitabine (NM283) when used alone and when valopicitabine is used together with
pegylated interferon in hepatitis C treatment failure patients. These results will be
compared against the results of treatment with pegylated interferon plus ribavirin, the
current standard therapy for treatment of hepatitis C viral infection.
Study to Evaluate Drug-drug Interaction Between Valopicitabine and Ribavirin
Completed
Novartis Pharmaceuticals
Phase 2
This study is being conducted to see if the investigational medication, valopicitabine, is
safe to use in combination with ribavirin, a drug approved by the FDA for treating hepatitis
C infection.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
